453 related articles for article (PubMed ID: 25964330)
1. Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid.
Tsai SY; Pokrass MJ; Klauer NR; Nohara H; Su TP
Proc Natl Acad Sci U S A; 2015 May; 112(21):6742-7. PubMed ID: 25964330
[TBL] [Abstract][Full Text] [Related]
2. Myristic acid hitchhiking on sigma-1 receptor to fend off neurodegeneration.
Ciesielski J; Su TP; Tsai SY
Receptors Clin Investig; 2016; 3(1):. PubMed ID: 27077074
[TBL] [Abstract][Full Text] [Related]
3. RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation.
Zhao D; Zhou Y; Huo Y; Meng J; Xiao X; Han L; Zhang X; Luo H; Can D; Sun H; Huang TY; Wang X; Zhang J; Liu FR; Xu H; Zhang YW
Cell Death Differ; 2021 Jan; 28(1):337-348. PubMed ID: 32908202
[TBL] [Abstract][Full Text] [Related]
4. Membrane association facilitates degradation and cleavage of the cyclin-dependent kinase 5 activators p35 and p39.
Minegishi S; Asada A; Miyauchi S; Fuchigami T; Saito T; Hisanaga S
Biochemistry; 2010 Jul; 49(26):5482-93. PubMed ID: 20518484
[TBL] [Abstract][Full Text] [Related]
5. Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Biochem Biophys Res Commun; 2002 Nov; 298(5):693-8. PubMed ID: 12419309
[TBL] [Abstract][Full Text] [Related]
6. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
Hisanaga S; Saito T
Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
[TBL] [Abstract][Full Text] [Related]
7. p35/Cyclin-dependent kinase 5 is required for protection against beta-amyloid-induced cell death but not tau phosphorylation by ceramide.
Seyb KI; Ansar S; Li G; Bean J; Michaelis ML; Dobrowsky RT
J Mol Neurosci; 2007; 31(1):23-35. PubMed ID: 17416967
[TBL] [Abstract][Full Text] [Related]
8. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.
Sun LH; Ban T; Liu CD; Chen QX; Wang X; Yan ML; Hu XL; Su XL; Bao YN; Sun LL; Zhao LJ; Pei SC; Jiang XM; Zong DK; Ai J
J Neurochem; 2015 Sep; 134(6):1139-51. PubMed ID: 26118667
[TBL] [Abstract][Full Text] [Related]
9. Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury.
Yousuf MA; Tan C; Torres-Altoro MI; Lu FM; Plautz E; Zhang S; Takahashi M; Hernandez A; Kernie SG; Plattner F; Bibb JA
J Neurochem; 2016 Jul; 138(2):317-27. PubMed ID: 26998748
[TBL] [Abstract][Full Text] [Related]
10. The levels of cdk5 and p35 proteins and tau phosphorylation are reduced during neuronal apoptosis.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Biochem Biophys Res Commun; 2001 Feb; 280(4):998-1002. PubMed ID: 11162625
[TBL] [Abstract][Full Text] [Related]
11. Kainate induces AKT, ERK and cdk5/GSK3beta pathway deregulation, phosphorylates tau protein in mouse hippocampus.
Crespo-Biel N; Canudas AM; Camins A; Pallàs M
Neurochem Int; 2007 Jan; 50(2):435-42. PubMed ID: 17116346
[TBL] [Abstract][Full Text] [Related]
12. Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Brain Res Mol Brain Res; 2002 Oct; 106(1-2):50-6. PubMed ID: 12393264
[TBL] [Abstract][Full Text] [Related]
13. CDK5 activator protein p25 preferentially binds and activates GSK3β.
Chow HM; Guo D; Zhou JC; Zhang GY; Li HF; Herrup K; Zhang J
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4887-95. PubMed ID: 25331900
[TBL] [Abstract][Full Text] [Related]
14. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro.
Town T; Zolton J; Shaffner R; Schnell B; Crescentini R; Wu Y; Zeng J; DelleDonne A; Obregon D; Tan J; Mullan M
J Neurosci Res; 2002 Aug; 69(3):362-72. PubMed ID: 12125077
[TBL] [Abstract][Full Text] [Related]
15. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.
Cruz JC; Tseng HC; Goldman JA; Shih H; Tsai LH
Neuron; 2003 Oct; 40(3):471-83. PubMed ID: 14642273
[TBL] [Abstract][Full Text] [Related]
16. Dendritic distribution of CDK5 mRNA and p35 mRNA, and a glutamate-responsive increase of CDK5/p25 complex contribute to tau hyperphosphorylation.
Tanaka T; Ohashi S; Takashima A; Kobayashi S
Biochim Biophys Acta Gen Subj; 2022 Jul; 1866(7):130135. PubMed ID: 35358667
[TBL] [Abstract][Full Text] [Related]
17. Two Degradation Pathways of the p35 Cdk5 (Cyclin-dependent Kinase) Activation Subunit, Dependent and Independent of Ubiquitination.
Takasugi T; Minegishi S; Asada A; Saito T; Kawahara H; Hisanaga S
J Biol Chem; 2016 Feb; 291(9):4649-57. PubMed ID: 26631721
[TBL] [Abstract][Full Text] [Related]
18. Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats.
Hung KS; Hwang SL; Liang CL; Chen YJ; Lee TH; Liu JK; Howng SL; Wang CH
J Neuropathol Exp Neurol; 2005 Jan; 64(1):15-26. PubMed ID: 15715081
[TBL] [Abstract][Full Text] [Related]
19. p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
Hallows JL; Iosif RE; Biasell RD; Vincent I
J Neurosci; 2006 Mar; 26(10):2738-44. PubMed ID: 16525053
[TBL] [Abstract][Full Text] [Related]
20. Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice.
Hallows JL; Chen K; DePinho RA; Vincent I
J Neurosci; 2003 Nov; 23(33):10633-44. PubMed ID: 14627648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
